The drug – a rosiglitazone-based medicine that controls blood glucose by increased the body’s sensitivity to insulin, so cells and muscles are able to use more for energy, reducing levels in the blood – was off the market in Europe and restricted in the United States for several years due to studies showing the drug raised the risk of heart disease.